Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study

OBJECTIVE: To determine whether the benefits of dapagliflozin in patients with type 2 diabetes and chronic kidney disease (CKD) in the Dapagliflozin And Prevention of Adverse Outcomes in CKD trial (DAPA-CKD) varied by background glucose-lowering therapy (GLT). RESEARCH DESIGN AND METHODS: We randomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Beernink, Jelle M., Persson, Frederik, Jongs, Niels, Laverman, Gozewijn D., Chertow, Glenn M., McMurray, John J.V., Langkilde, Anna Maria, Correa-Rotter, Ricardo, Rossing, Peter, Sjöström, C. David, Toto, Robert D., Wheeler, David C., Heerspink, Hiddo J.L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020024/
https://www.ncbi.nlm.nih.gov/pubmed/36662635
http://dx.doi.org/10.2337/dc22-1514

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020024/
https://www.ncbi.nlm.nih.gov/pubmed/36662635
http://dx.doi.org/10.2337/dc22-1514

Ejemplares similares